Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, underperforming the Shenwan A Index by 0.7 percentage points [4][5]. - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical for assessing market trends and performance [4][9]. - Notable company performances include: - Aimei Ke reported a revenue of 2.453 billion yuan for 2025, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [10]. - Juzi Biotechnology's revenue was 5.519 billion yuan, a slight decrease of 0.4%, with a net profit of 1.915 billion yuan, down 7.2% [10] [11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector is currently underperforming the market, with specific indices showing declines [4][5]. - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4% [4]. Company Highlights - Aimei Ke's Q4 2025 revenue was 588 million yuan, down 9.61% year-on-year, with a net profit of 198 million yuan, down 46.85% [10]. - Juzi Biotechnology's effective skincare products generated 4.337 billion yuan in revenue, a 0.8% increase, while medical dressings saw a 4.8% decline [11]. Market Trends - The report highlights the importance of upcoming earnings disclosures from major companies, which are expected to provide insights into market recovery and performance [4][9]. - The overall retail sales of cosmetics in January-February 2026 grew by 4.5%, indicating a relative resilience in the beauty sector compared to the overall retail market [14]. E-commerce and Brand Performance - The report provides data on e-commerce performance, noting that domestic brands are gaining market share, with significant growth in GMV for brands like Shangmei [13]. - The report emphasizes the competitive landscape, with domestic brands increasingly challenging international players in market share [21][23].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, which is 0.7 percentage points worse than the Shenwan A Index [4][5] - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical to monitor [4][10] - The report highlights the performance of major companies, noting that Aimeike's revenue for 2025 is projected at 2.453 billion yuan, a year-on-year decrease of 18.94% [11] Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4%, indicating varied performance within the sector [4][5] - The report notes that the beauty care sector is entering earnings season, with several companies set to announce their financial results [10] Company Highlights - Aimeike's 2025 performance shows a revenue of 2.453 billion yuan, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [11] - Juzi Biotechnology reported a slight revenue decline of 0.4% to 5.519 billion yuan, with a net profit decrease of 7.2% [11] - The report emphasizes the importance of product matrix improvement and collaboration for growth in Aimeike's future performance [12] Market Trends - The report indicates that the retail sales of cosmetics in China grew by 4.5% year-on-year in the first two months of 2026, outperforming overall retail growth [16] - The report also notes that the domestic market is seeing a shift towards local brands, with significant growth in market share for domestic products [23] Industry Dynamics - The report discusses the strategic partnership between L'Oréal and NVIDIA to enhance AI research in beauty products, reflecting a trend towards technological integration in the industry [20] - The competitive landscape is evolving, with domestic brands gaining ground against international players, particularly in the skincare segment [23]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in the industry due to slowing growth and increased competition [1][2]. Financial Performance - For H1 2025, the company achieved a revenue of 1.299 billion yuan, down 21.59% year-on-year; net profit attributable to shareholders was 789 million yuan, down 29.57% year-on-year; and net profit excluding non-recurring items was 722 million yuan, down 33.70% year-on-year [1]. - In Q2 2025, revenue was 636 million yuan, down 25.11% year-on-year; net profit attributable to shareholders was 346 million yuan, down 41.75% year-on-year; and net profit excluding non-recurring items was 320 million yuan, down 42.83% year-on-year [1]. Profitability Metrics - The gross margin for H1 2025 was 93.44%, a decrease of 1.48 percentage points year-on-year; the net profit margin attributable to shareholders was 60.77%, down 6.88 percentage points year-on-year [2]. - In Q2 2025, the gross margin was 93.00%, down 2.26 percentage points year-on-year; the net profit margin attributable to shareholders was 54.38%, down 15.53 percentage points year-on-year [2]. Expense Ratios - The sales expense ratio for H1 2025 was 11.10%, an increase of 2.58 percentage points year-on-year; the management expense ratio was 5.34%, up 1.25 percentage points year-on-year; and the R&D expense ratio was 12.05%, up 4.46 percentage points year-on-year [2]. - In Q2 2025, the sales expense ratio was 12.39%, up 3.70 percentage points year-on-year; the management expense ratio was 5.99%, up 1.88 percentage points year-on-year; and the R&D expense ratio was 15.42%, up 7.38 percentage points year-on-year [2]. Product Performance - Revenue from solution-type injection products in H1 2025 was 744 million yuan, down 23.79% year-on-year, accounting for 57.27% of total revenue; gross margin was 93.15%, down 0.83 percentage points year-on-year [2]. - Revenue from gel-type injection products was 493 million yuan, down 23.99% year-on-year, accounting for 37.97% of total revenue; gross margin was 97.75%, down 0.23 percentage points year-on-year [2]. - Revenue from freeze-dried powder injection products was 19 million yuan, accounting for 1.50% of total revenue; revenue from facial implant lines was 3 million yuan, down 4.56% year-on-year, accounting for 0.26% of total revenue [2]. Other Income - Other income amounted to 39 million yuan, an increase of 38.88% year-on-year, accounting for 3.01% of total revenue [3]. R&D and Pipeline - The company has a strong R&D pipeline, with products such as botulinum toxin type A and minoxidil lotion submitted for review, and a local anesthetic cream application accepted for listing; other products are in clinical trials, which are expected to strengthen the company's leading position in the medical aesthetics sector [4]. Strategic Acquisition - The company completed the payment for 95% of the transaction price for the acquisition of South Korean REGEN, a key move in its internationalization strategy, which is expected to enhance its leading position in the medical aesthetic injection market and facilitate overseas business expansion [5]. Future Outlook - The company has adjusted its revenue and profit forecasts for 2025-2027 due to industry slowdown and increased competition, projecting revenues of 2.724 billion yuan, 3.190 billion yuan, and 3.715 billion yuan, and net profits of 1.630 billion yuan, 1.942 billion yuan, and 2.343 billion yuan for the respective years [5].

Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [6][17]. Core Views - The company is experiencing a temporary pressure on performance in H1 2025, with a revenue of 1.299 billion yuan, down 21.59% year-on-year, and a net profit of 789 million yuan, down 29.57% year-on-year. The second quarter of 2025 also shows a decline in revenue and net profit [1][2]. - Despite the current challenges, the company has a rich pipeline of products and strong R&D capabilities, with several products in various stages of development, including the injection of botulinum toxin type A and minoxidil lotion [4]. - The acquisition of Korean company REGEN is a key strategic move for the company's international expansion, enhancing its position in the aesthetic injection market and facilitating the entry of its products into international markets [5]. Financial Performance - In H1 2025, the gross margin was 93.44%, a decrease of 1.48 percentage points year-on-year, while the net profit margin was 60.77%, down 6.88 percentage points year-on-year. The R&D expense ratio increased to 12.05%, up 4.46 percentage points year-on-year [2]. - The revenue from solution-type injection products was 744 million yuan, down 23.79% year-on-year, while gel-type injection products generated 493 million yuan, also down 23.99% year-on-year [3]. - The company expects revenues for 2025-2027 to be 2.724 billion yuan, 3.190 billion yuan, and 3.715 billion yuan respectively, with net profits of 1.630 billion yuan, 1.942 billion yuan, and 2.343 billion yuan respectively [5]. Market Position - The company is facing a slowdown in industry growth and intensified competition, which is impacting the growth of its core products [3]. - The company maintains a leading position in the aesthetic medical market, supported by its strong product pipeline and recent acquisitions [5].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation of stock performance that exceeds market performance by 10% to 20% over the next six months [11]. Core Views - The company experienced a revenue decline in the first half of 2025, achieving 1.299 billion yuan, a year-over-year decrease of 21.59%. The net profit attributable to shareholders fell by 29.57% to 789 million yuan [4]. - The report highlights that the company is entering a low base period in the second half of the year, which may facilitate a return to growth [7]. - The company has a diverse product matrix, with several products in the registration phase, which could contribute to future revenue growth [8]. Summary by Sections Company Overview - The company operates in the retail industry with a total market capitalization of 55.6 billion yuan and a total share capital of 303 million shares [1]. Financial Performance - The company reported a gross margin of 93.44% and a net margin of 60.9% in the first half of 2025, with a basic EPS of 2.62 yuan [4][7]. - Revenue for 2023 is projected at 2.869 billion yuan, with a year-over-year growth of 48%, followed by a slight increase to 3.026 billion yuan in 2024 [6]. Future Projections - The report projects revenues of 1.781 billion yuan, 2.142 billion yuan, and 2.503 billion yuan for 2025, 2026, and 2027 respectively, reflecting a downward adjustment from previous estimates [8]. - The company is expected to maintain a robust product offering, which may enhance consumer solutions and drive growth in the upcoming periods [8].